Home > News > 33/First UK experience of cardiac contractility modulation therapy in patients with heart failure and reduced ejection fraction
Devices
Read Time: 2 mins

33/First UK experience of cardiac contractility modulation therapy in patients with heart failure and reduced ejection fraction

Published Online: September 27th 2010 European Journal of Arrhythmia & Electrophysiology. 2020;6(Suppl. 1):abstr33
Authors: R Dulai (Presenting Author) - East Sussex Healthcare NHS Trust, Eastbourne; S Badiani - East Sussex Healthcare NHS Trust, Eastbourne; RA Veasey - East Sussex Healthcare NHS Trust, Eastbourne; S Furniss - East Sussex Healthcare NHS Trust, Eastbourne; N Patel - East Sussex Healthcare NHS Trust, Eastbourne; N Sulke - East Sussex Healthcare NHS Trust, Eastbourne
Quick Links:
Article
Article Information
Article:

Background: Cardiac Contractility Modulation therapy is a novel device-based technology, which may be used in selected heart failure patients. CCM therapy involves applying biphasic, high-voltage (≈7.5 V) and long-duration (≈20 milliseconds) electric signals to the right ventricular septal wall during the absolute myocardial refractory period, which invokes biochemical and cellular changes in the failing myocardium thus improving contractility. The aim of this study is to report the outcomes in the first ten patients implanted with a CCM device in the United Kingdom.

Methods: This was a retrospective study. 10 patients who met the inclusion criteria (EF 25-45%, NYHA class 3 or 4 and QRS duration less than 130 ms) were implanted with a CCM device in 2018. As part of their follow-up they underwent regular review by the heart failure team. We report the changes in ejection fraction, NYHA class and The Minnesota Living with Heart Failure Questionnaire (MLHFQ) scores over the follow-up period.

Results: The mean age of the patients was 68.3 ± 7.8. Six of the patients were male and the majority of patients (90 %) had an ischaemic cardiomyopathy. The average follow-up in months was 21.30 ± 2.2. Overall, the ejection fraction improved from 26.2% ± 4.4% to 31.8% ± 3.6% at final follow-up (p=0.40) and quality of life as measured by the MLHFQ improved significantly from 56.3 ± 19.6 to 34.0 ± 21.8 (p≤0.01). (Figure 1) All patients improved at least one NYHA class. Overall, the NYHA class improved from 2.80 ± 0.92 to 1.7 ± 0.68 (p=0.77).

Conclusion: CCM therapy resulted in an improvement in ejection fraction and quality of life in this patient cohort, which is consistent with previous clinical trial data. CCM therapy provides a potential new treatment option for these patients who would not be eligible for cardiac resynchronisation therapy.

Article Information:

Further Resources

Share this Article
Related Content In Devices
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72